Highlights from Issue 3, 2025: Reflections on Leadership, Innovation, and Rare Diagnoses
Ibnosina Journal of Medicine and Biomedical Sciences · 01.09.2025 · 17 (03) · 85
DOI: 10.1055/s-0045-1811568 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ibnosina Journal of Medicine and Biomedical Sciences, erschienen am 01.09.2025. Verfasst von Salem A. Beshyah. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Welcome to the third issue of 2025. This issue is a fairly small one. We have a review, four original articles, a pathology corner piece, and three case reports. We have a professional review on becoming a successful chief medical officer (CMO). It is a quick primer revisiting critical issues needed by those who aspire to become CMOs, often called medical directors. Many senior clinicians may mistakenly believe that their rise to a medical director position is a recognition of their clinical excellence. The primer revisited the skills, qualifications, and attributes needed to become a successful CMO. The four original articles include a variety of clinical, educational, and basic science interests. They also come from different parts of the world, Saudi Arabia, Türkiye, and as far as Uzbekistan. The first is a prospective randomized controlled study on the efficacy of sacral erector spinae plane block for postoperative pain management in hemorrhoid and pilonidal sinus surgery by Koç et al. The second is an analysis of the prognostic significance of serum soluble endoglin (CD105) levels in patients with acute myeloid leukemia by Soydan et al. Next, the impact of clinical teaching behavior on learning experience of nursing students by Mariano et al. Lastly, a histological and immunohistochemical study of the age-dependent skeletal muscle response to mechanical injury under halothane anesthesia in rats by Tilavov et al. The pathology corner has allergic granulomatous contact dermatitis, which reacts to metal particles used in earlobe piercing. The three case reports are on (1) congenital basaloid linear nevus in a 6-month-old child and (2) a family with epilepsy and dyskinesia due to a homozygous PRRT2 gene mutation. Third is a mixed bag of clinical and ethical dilemma of balancing benefit and risk when facing the wish of continuing glucagon-like peptide-1 receptor agonists for successful weight management after sustaining a mild allergic reaction. The case raises several legal, professional, and clinical discussion points. The Libyan medical community has recently lost a pioneering surgeon, teacher, and researcher, Professor Ali Elhamel, MD, FRCS (October 24, 1946–March 19, 2025). We are grateful to Professor Salem Abugassa for providing an appropriate obituary. We hope you have an enjoyable and useful reading. Author's Contributions Single. Compliance with Ethical Principles No ethical approval is required. Publication History Article published online: 26 August 2025 © 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
Zitieren
APA
Beshyah, S. A. (2025). Highlights from Issue 3, 2025: Reflections on Leadership, Innovation, and Rare Diagnoses. Ibnosina Journal of Medicine and Biomedical Sciences, 17(03), 85. https://doi.org/10.1055/s-0045-1811568
Vancouver
Beshyah SA. Highlights from Issue 3, 2025: Reflections on Leadership, Innovation, and Rare Diagnoses. Ibnosina Journal of Medicine and Biomedical Sciences. 2025;17(03):85. doi:10.1055/s-0045-1811568
BibTeX
@article{Beshyah2025,
author = {Beshyah, Salem A.},
title = {Highlights from Issue 3, 2025: Reflections on Leadership, Innovation, and Rare Diagnoses},
journal = {Ibnosina Journal of Medicine and Biomedical Sciences},
year = {2025},
volume = {17},
number = {03},
pages = {85},
doi = {10.1055/s-0045-1811568}
}
EUVIMED